CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The TOPFIBRO project focuses on developing OXC-201, a novel treatment for Idiopathic Pulmonary Fibrosis (IPF). It aims to demonstrate the drug's efficacy in improving lung function and safety through preclinical and clinical studies, addressing a significant unmet need in IPF therapy.
Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease with no curative therapies.
Approved therapies for IPF have a high rate of discontinuation among patients due to adverse side-effects and present a high unmet need for effective therapies.
Oxcia’s OXC-201 is a ground-breaking novel approach for treatment of IPF, based on completely new biology. OXC-201 targets profibrotic and proinflammatory cascades at an early stage on a transcriptional level, and is expected to efficiently prev…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
